Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.97 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.71 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.71 |
| ▸ | BPTF | Q12830 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651796 | 1.00 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL652246 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL652245 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL654313 | 0.91 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL654312 | 0.91 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL654311 | 0.91 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30556707 | 0.84 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL5034095 | 0.83 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL6187382 | 0.83 | CHRNB2 (0.82) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL930530 | 0.83 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102863441-A | Clic central nervous system active agents | ABBOTT LAB | 2013-01-09 | — | — | CN | claimed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | claimed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | claimed |
| CN-101935322-A | Diazabicyclic central nervous system active agents | ABBOTT LAB | 2011-01-05 | — | — | CN | claimed |
| CN-101357915-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2009-02-04 | — | — | CN | claimed |
| EP-1274710-B1 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH AS (DK) | 2005-02-23 | — | — | EP | claimed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | claimed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | claimed |
| CN-1440410-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2003-09-03 | — | — | CN | claimed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | claimed |
| EP-1274710-A2 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NeuroSearch A/S (DK) | 2003-01-15 | — | — | EP | claimed |
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | NEUROSEARCH A/S (DK) | 2003-01-02 | — | — | US | claimed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | claimed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2001044243-A2 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH A/S (DK) | 2001-06-21 | — | — | WO | claimed |
| CN-102863441-A | Clic central nervous system active agents | ABBOTT LAB | 2013-01-09 | — | — | CN | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | NEUROSEARCH A/S (DK) | 2003-01-02 | — | — | US | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001044243-A2 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH A/S (DK) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | CHRNA2, CHRNA5, CHRNA6 | CHRNB2 6/4885CHRNA4 8/4885CHRNA7 4/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CHRNB2 10/4885CHRNA4 11/4885CHRNA7 5/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNA7 6/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNA7 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.